OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Taieb on Findings from a Post-hoc Analysis of TAS-102 Plus Bevacizumab in Refractory mCRC

June 20th 2023

Julien Taieb, MD, PhD, discusses key findings from a post-hoc analysis of the phase 3 SUNLIGHT trial of combination of trifluridine/tipiracil with bevacizumab in patients with refractory metastatic colorectal cancer.

Dr Phillips on the Preliminary Efficacy of Acalabrutinib Plus BR in MCL

June 20th 2023

Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.

Dr Borad on the Initial Efficacy of RLY-4008 in FGFR2 Fusion–Positive Cholangiocarcinoma

June 20th 2023

Mitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.

Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast Cancer

June 19th 2023

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.

Dr Svoboda on the Implications of Nivolumab Plus AVD in Classical Hodgkin Lymphoma

June 19th 2023

Jakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.

Dr Vidula on the Evaluation of Talazoparib in BRCA1/2-Mutated Metastatic Breast Cancer

June 19th 2023

Neelima Vidula, MD, discusses an ongoing phase 2 study evaluating the highly potent PARP inhibitor talazoparib in patients with somatic BRCA1/2-mutated metastatic breast cancer.

Dr Patel on the Efficacy of Ide-Cel in Patients With High-Risk R/R Multiple Myeloma

June 19th 2023

Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.

Dr Jacobs on the Preliminary Efficacy of TNB-486 in R/R Follicular Lymphoma

June 19th 2023

Ryan Jacobs, MD, hematologist and medical oncologist, Levine Cancer Institute, Atrium Health, discusses early responses with the novel CD19 and CD3 T-cell engager TNB-486 in relapsed/refractory follicular lymphoma according to a phase 1 study.

Dr Kim on the HARMONIC Trial of LP-300 in Advanced Lung Cancer

June 19th 2023

Edward S. Kim, MD, MBA, discusses the investigation of LP-300 plus chemotherapy in the phase 2 HARMONIC trial in patients with advanced lung adenocarcinoma.

Dr Shah on Long-Term Survival Data For Pirtobrutinib in BTK Inhibitor–Pretreated R/R MCL

June 16th 2023

Nirav N. Shah, MD, discusses the long-term efficacy of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma with previous exposure to covalent BTK inhibitors, according to updated data from the phase 1/2 BRUIN trial.

Dr Kremyanskaya on the Efficacy of Rusfertide in Phlebotomy-Dependent Polycythemia Vera

June 16th 2023

Marina Kremyanskaya, MD, PhD, discusses key efficacy data for rusfertide in the phase 2 REVIVE trial of phlebotomy-dependent polycythemia vera.

Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL

June 16th 2023

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Dr Gupta on the 4-Year Efficacy of the EV-103 Trial in Urothelial Carcinoma

June 15th 2023

Shilpa Gupta, MD, discusses the 4-year safety and efficacy data derived from the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma.

Dr Hitchcock on the Rationale for the ERAsur Trial in Limited mCRC

June 15th 2023

Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.

Dr Hutson on the Final OS Analysis of the CLEAR Study in Advanced RCC

June 15th 2023

Thomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.

Dr Elkhanany on Biological Drivers of Progression in ER+ Metastatic Breast Cancer

June 15th 2023

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches.

Dr Miron on Molecular Alterations in Intraductal Carcinoma of the Prostate

June 15th 2023

Benjamin Miron, MD, discusses findings and clinical implications from a study investigating molecular alterations in patients with intraductal carcinoma of the prostate.

Dr Burke on the Influence of the SHINE and TRIANGLE Trials on Ibrutinib Use in MCL

June 15th 2023

John M. Burke, MD, discusses the influence of two key BTK inhibitor combination studies on therapeutic approaches for patients with previously untreated mantle cell lymphoma.

Dr Bose on the Use of Zilurgisertib With/Without Ruxolitinib to Reduce Anemia in Myelofibrosis

June 15th 2023

Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis.

Dr Lee on the Investigation of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

June 15th 2023

Hans C. Lee, MD, discusses the investigation of the BCMA x CD3 bispecific antibody linvoseltamab in patients with relapsed/refractory multiple myeloma.